Hyderabad: India needs to plan the third dose of Covid-19 vaccine for the population in 2022 to fight various virus mutations, the top scientists said.
Said it comes even when the country struggles on the front of the vaccination, with more than 22% of the population after receiving at least one dose, and around 5.4% get both in the second week of July.
Matched that two available vaccines are wide – Covaxin and Covishield – in India prevent the severity of the disease.
However, the scientific community believes two vaccine doses may not be enough, because the Raging Delta Plus variant has an additional mutation (K417N) and two lines (AY.1 and AY.2), with the nature of immune avoidance.
“How long does the vaccine protection goes on? Claims vary.
However, reasonable predictions indicate that protective antibodies can last for six months after the vaccination schedule is complete,” Professor G Padmanaban, Advisor to the Senior Science Innovation (BIRAC), the Biotechnology Department told TII.
“There may be longer protective cells.
All of this can vary between individuals.
This is where he deserves planned for third-dose vaccination in the mid 2022.” Padmanaban, former Director of the Indian Institute of Science, Bengaluru, said that while most mutations It tends to deactivate viruses, someone cannot override new mutations that are more contagious.
“So, someone hopes that the third dose offers adequate protection until the virus loses its infectivity – and is tamed to be more visitors to the annual flu – if it does not give us a total break,” he said.
While India contains the first wave, the second, which began around March 2021 hit the country hard.
After showing a number of decreasing signs, the number of positive cases returned to the north, raising the third wave concern.
A senior health expert with the epidemiological division and infectious disease ICMR said it was important to discuss new strategies to load viruses, improve health infrastructure and prevent more death.
The former center of the Director and Cellular Biology Advisor and Molecular Dr.
Rakesh Mishra said the country was at an important stage, and in the next five-six months, the initial vaccination of two doses must be resolved.
“After completion, the third dose is fine.
We plan the third dose for the population as one of the strategies to be discussed,” Mishra said.
Padmanaban said a strategy to protect against a new variant could make a new vaccine against the Delta / Delta Plus variant, using an inactive virus (similar to covaxin) or a sub-unit vaccine (similar to covishield).
“The trial will be needed to determine whether the ‘mutant’ vaccine is as effective,” he said.
“For now, the appropriate Covid-19 behavior, wearing facial masks in particular, and vaccination is the only proven strategy to curb a pandemic,” he said.